Lethal to Livable: How Gleevec changed cancer careView All Events
Join us in celebrating the 20th anniversary of the FDA approval of Gleevec, the revolutionary drug developed by OHSU Knight Cancer Institute Director, Dr. Brian Druker.
This conversation was livestreamed on May 10.
Help support the Knight Cancer Institute continue to make groundbreaking discoveries to bring new hope to patients more quickly – MAKE A GIFT TODAY
For more information, please contact:
Caitlin Wilson, Senior Director of Development
Twenty years ago, on May 10, 2001, the Food & Drug Administration (FDA) approved Gleevec for use in treating patients with a once-deadly cancer called Chronic Myeloid Leukemia (CML). Since that date, thousands of lives have been saved, and Gleevec has set the stage for other pioneering discoveries in the quest to end cancer as we know it.
Hear from patients whose lives were saved by a breakthrough medication to manage CML; hear Dr. Brian Druker, the physician scientist who pioneered Gleevec, tell how he overcame skepticism on his way to FDA approval; and hear from others at the OHSU Knight Cancer Institute as they talk about how Gleevec paved the way for a transformative approach to cancer research and care.
Brian Druker, M.D.
JELD-WEN Chair of Leukemia Research
Director, OHSU Knight Cancer Institute
Gordon B. Mills, M.D., Ph.D.
Wayne and Julie Drinkward Endowed Chair, Precision Oncology, Knight Cancer Institute
Director, Precision Oncology, OHSU Knight Cancer Institute
Director, SMMART Trials, OHSU Knight Cancer Institute
Professor, Cell, Developmental and Cancer Biology
Shivaani Kummar, M.D., FACP
Margaret and Lester DeArmond University Chair of Molecular Oncology
Division head, Hematology and Medical Oncology, OHSU Knight Cancer Institute
Associate Director for Clinical Research
Co-Director, Center for Experimental Therapeutics
Assistant Director of Research Collaborations for the Precision Oncology SMMART Clinical Trials Program
Hai Pham, D.M.D.
Chair of the Knight Cancer Institute Council